Kronos Bio Inc. (KRON): Price and Financial Metrics
GET POWR RATINGS... FREE!
KRON Stock Price Chart Interactive Chart >
KRON Price/Volume Stats
| Current price | $2.56 | 52-week high | $9.51 |
| Prev. close | $2.37 | 52-week low | $1.35 |
| Day low | $2.30 | Volume | 322,300 |
| Day high | $2.62 | Avg. volume | 420,283 |
| 50-day MA | $1.95 | Dividend yield | N/A |
| 200-day MA | $3.52 | Market Cap | 145.66M |
Kronos Bio Inc. (KRON) Company Bio
Kronos Bio, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of novel cancer therapeutics. The company's product engine focuses on dysregulated transcription factors and the transcriptional regulatory networks that drive oncogenic activity. Its lead product candidate is entospletinib, a selective inhibitor targeting spleen tyrosine kinase in acute myeloid leukemia patients. The company is also developing KB-0742, an orally bioavailable inhibitor of cyclin dependent kinase 9 for the treatment of MYC-amplified solid tumors. Kronos Bio, Inc. is founded in 2017 and is headquartered in San Mateo, California.
Latest KRON News From Around the Web
Below are the latest news stories about KRONOS BIO INC that investors may wish to consider to help them evaluate KRON as an investment opportunity.
Deals, data kick off biotech's big JPM WeekBiotech companies are trying to get in front of investors and potential partners — and regulators — with news ahead of the big J.P. Morgan Healthcare Conference in San Francisco. |
Kronos Bio’s stock rallies after announcing drug-discovery deal with RocheMARKET PULSE Shares of Kronos Bio Inc. (KRON) jumped 25% in premarket trading on Monday after the company announced a development deal with Roche Holding’s (CH:ROG) Genentech. Kronos has a drug discovery platform that will be used to support Genentech’s research in small-molecule drugs for cancer. |
Kronos Bio Announces Discovery Collaboration with Genentech to Advance Novel Therapies Against Transcriptional Targets in OncologyKronos Bio will receive a $20 million upfront payment and could receive up to an additional $554 million in milestone payments Agreement will leverage Kronos Bio’s expertise in transcriptional regulatory networks and its proprietary drug discovery platform SAN MATEO, Calif. and CAMBRIDGE, Mass., Jan. 09, 2023 (GLOBE NEWSWIRE) -- Kronos Bio, Inc. (Nasdaq: KRON), a company dedicated to transforming the lives of those affected by cancer, announced today that it has entered into a discovery collabor |
Do investors need to be concerned about Kronos Bio Inc. (KRON)?As of Friday, Kronos Bio Inc.’s (NASDAQ:KRON) stock closed at $1.49, up from $1.46 the previous day. While Kronos Bio Inc. has overperformed by 2.05%, investors are advised to look at stock chart patterns for technical insight. Within its last year performance, KRON fell by -90.32%, with highs and lows ranging from $15.80 to $1.40, […] |
We're Keeping An Eye On Kronos Bio's (NASDAQ:KRON) Cash Burn RateJust because a business does not make any money, does not mean that the stock will go down. For example, although... |
KRON Price Returns
| 1-mo | 71.81% |
| 3-mo | -12.33% |
| 6-mo | -38.01% |
| 1-year | -71.43% |
| 3-year | N/A |
| 5-year | N/A |
| YTD | 58.02% |
| 2022 | -88.08% |
| 2021 | -54.50% |
| 2020 | N/A |
| 2019 | N/A |
| 2018 | N/A |
Loading social stream, please wait...